Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

demonstrated encouraging potential in initial clinical studies," said David Tabagari, M.D., Ph.D., the head of Medulla Immunotherapy and Chemotherapy Clinic and principal investigator of the bavituximab breast cancer trial being conducted in the Republic of Georgia. "We are pleased to have the opportunity to conduct the first Phase II trial of this potentially valuable new approach to treating cancer."

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and about 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has recently received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol testing
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... in accordance with Securities and Exchange Commission rule 10b5-1. ... Corporation, is a minority owner of this entity that ... Herbert does not have control of this entity, but ... for a portion of the shares owned by that ...
(Date:3/27/2015)...  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , today reported financial ... 31, 2014.  The Company reported a ... for the three months ended December 31, 2014.  This ...
(Date:3/26/2015)... Louisville, CO (PRWEB) March 26, 2015 ... agency has formed a strategic alliance with Designing Gig ... to their clients. , “Forging this alliance ... company. Now we can extend a comprehensive, end-to-end, ... design, development, strategy, and execution,” said Chuck Miller, president ...
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
Breaking Biology Technology:Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... tiny defects in the lines, dots and other shapes ... engineers have now found a way to literally melt ... improve chip quality without increasing fabrication cost. , The ... Nanotechnology, enables more precise shaping of microchip components than ...
... Researchers at Fred Hutchinson Cancer,Research Center have a ... first systematic surveillance program of men with prostate,cancer to ... wait and when,to treat the disease. The project was ... Peter Nelson, M.D., of the Hutchinson Center,s Clinical ...
... Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO) announced today that ... Pulmo BioTech Chief Executive Officer Garry McCann said that he ... and that Rajiv,s,experience and financial acumen would be of great ... Phase I Human Trials and then into Phase,II., Rajiv ...
Cached Biology Technology:Melting defects could lead to smaller, more powerful microchips 2Melting defects could lead to smaller, more powerful microchips 3Melting defects could lead to smaller, more powerful microchips 4When to Wait and When to Treat? New Program Will Search for Biomarkers in Men With Prostate Cancer to Help Find an Answer 2When to Wait and When to Treat? New Program Will Search for Biomarkers in Men With Prostate Cancer to Help Find an Answer 3Pulmo BioTech Announces Appointment of Chief Financial Officer 2Pulmo BioTech Announces Appointment of Chief Financial Officer 3
(Date:3/17/2015)... March 17, 2015  MecklerMedia Corporation (OTCQX: MECK) ... for service robots ever held in ... on May 11-13, 2015 at the Javits Convention ... the event include: Acorn Product Development; Axis NJ; ... Kinova Robotics; Littler; NewBotic Corporation; Neya Systems LLC; ...
(Date:3/12/2015)... The mascots of the Atlantic Coast Conference ... Wake Forest Baptist Medical Center. They stopped by as ... Men,s Basketball Tournament. Young patients enjoyed bonding with their ... autographs. Brenner Children,s Hospital is the pediatric ... children,s hospital in northwest North Carolina ...
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... the "Access Control Market by Product, Application & ... report to their offering. , This ... to reach $10.4 billion by 2020, with an estimated ... report covers the products types such as contact cards ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... New Mexico State University researchers are testing advanced eye-scanning ... system for animal health. , "Retinal scans are part ... Manny Encinias, livestock specialist at NMSU's Clayton Livestock Research ... the eyeball and records the pattern of veins in ...
... central China has documented that illegal blood donation practices led ... and plasma donors during the 1980s and early 1990s, and ... their risk of infection as well, according to an article ... Diseases, now available online. , Some blood donation facilities in ...
... yield of a major crop by stopping its seedpods from ... important oilseed crop in India after groundnut. It is grown ... the seedpods open naturally to disperse their seeds at different ... shatter' also makes it difficult for farmers to rotate crops ...
Cached Biology News:Retinal scans eyed for New Mexico show cattle 2Retinal scans eyed for New Mexico show cattle 3Past illegal blood donation in China linked to hepatitis C virus infection 2
Rabbit Serum New Zealand or California Origin...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Human ICAT Affinity Purified Polyclonal Ab...
... [APS 26] to Presenilin 2 Alzheimer's ... of the disease carry mutations in the ... precursor protein (APP). These disease-linked mutations result ... of amyloid-beta (main component of amyloid deposits ...
Biology Products: